Even younger nightshift workers shown to need to pee more, worsening quality of life
(European Association of Urology) Millions of people work nights, but increasingly scientists are finding that night work is associated with health problems. Now a group of Italian scientists has found that nightshift workers also need to pee more, leading to a deteriorating quality of life for many workers, including care workers. This is also true of younger subjects, who would not normally be expected to report an overactive bladder. This work is reported at the European Association of Urology Congress in Barcelona. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 15, 2019 Category: International Medicine & Public Health Source Type: news

Bioness StimRouter(R) Neuromodulation System Receives European CE Mark Approval for the Treatment of Overactive Bladder (OAB)
FDA-Approved StimRouter Continues to Improve the Lives of Chronic Pain Patients in the United States VALENCIA, Calif., Feb. 19, 2019 -- (Healthcare Sales & Marketing Network) -- Bioness, Inc., the leading provider of state-of-the-art, clinically suppor... Devices, Neurology, Urology, Regulatory Bioness, StimRouter, Neuromodulation, Overactive Bladder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 19, 2019 Category: Pharmaceuticals Source Type: news

A Novel Tibial Nerve Stimulation Device for OAB A Novel Tibial Nerve Stimulation Device for OAB
Could this ambulatory transcutaneous tibial nerve stimulation device be an effective treatment option for patients with overactive bladder?Translational Andrology and Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2019 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Light-up 'belt' that shines on the bladder could stop embarrassing leaks
The surgically implanted device is designed to combat overactive bladder — which affects around eight million people in Britain. (Source: the Mail online | Health)
Source: the Mail online | Health - January 22, 2019 Category: Consumer Health News Source Type: news

Closed-loop device uses light to control overactive bladder
Researchers developed this small device implanted around the bladder of a rat to provide closed-loop bladder control. It uses light signals from tiny LEDs to activate nerve cells in the bladder. (Image courtesy of Gereau Lab, Washington University) A team of neuroscientists and engineers has developed a tiny, implantable, closed-loop device that may replace medication or electronic stimulators for bladder disorders. The team from Washington University School of Medicine in St. Louis, the University of Illinois at Urbana-Champaign, and the Feinberg School of Medicine at Northwestern University in Chicago created a soft, imp...
Source: Mass Device - January 7, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Neuromodulation/Neurostimulation News Well Research & Development Urology feinbergschoolofmedicineatnorthwesternuniversity University of Illinois at Urbana-Champaign Washington University School of Medicine Source Type: news

Risk of 4 Pelvic Floor Disorders Associated With Delivery Mode (CME/CE)
(MedPage Today) -- Lower risk of stress urinary incontinence, overactive bladder, and pelvic organ prolapse with cesarean delivery than with surgical and non-surgical vaginal births (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - December 23, 2018 Category: OBGYN Source Type: news

Incontinence Drug May Help Ease Severe Hot Flashes
Oxybutynin, a drug widely used to treat urinary incontinence caused by an overactive bladder, helps treat hot flashes in breast cancer survivors and women who did not have breast cancer but who were bothered by frequent or severe menopausal symptoms, new research shows. (Source: WebMD Health)
Source: WebMD Health - December 17, 2018 Category: Consumer Health News Source Type: news

FDA Approves Smart Programmer for Medtronic Neuromodulation System
FDA approved a new smart programmer for Medtronic's InterStim system, which provides sacral neuromodulation therapy for the treatment of overactive bladder (OAB), chronic fecal incontinence (FI), and non-obstructive urinary retention. The new programmer streamlines multiple devices into a single, intuitive, touchscreen Samsung mobile device and enables clinicians to personalize each patient's care and allows patients to manage their therapy simply and discreetly, Medtronic said. According to the company, more than 37 million adults in the United States (almost one in six) suffer from OAB and nearly 20 million Americans (ab...
Source: MDDI - December 17, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Medtronic wins FDA nod for InterStim sacral neuromod programmer
Medtronic (NYSE:MDT) said today that the FDA approved its InterStim smart programmer, designed to work with the company’s InterStim sacral neurmodulation system intended for tor treating overactive bladder, chronic fecal incontinence and non-obstructive urinary retention. The newly cleared smart programmer is run on a Samsung Electronics (LON:BC94) mobile device and allows clinicians to personalize patient care and manage therapy from a single access point, the Fridley, Minn.-based medical giant said. “The incorporation of consumer technology in medical device solutions, such as the InterStim sys...
Source: Mass Device - December 17, 2018 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Regulatory/Compliance Medtronic samsung Source Type: news

Implantable Device May Relieve Urinary Urge Incontinence in OAB Implantable Device May Relieve Urinary Urge Incontinence in OAB
A small, nickel-sized, battery-powered implant (eCoin) appears to relieve urinary urge incontinence (UUI) associated with overactive bladder (OAB) syndrome by stimulating the tibial nerve, according to a new single-arm trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 30, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Axonics adds $18m to $120m IPO
Axonics Modulation Technologies (NSDQ:AXNX) said today that the underwriters behinds its $120 million initial public offering exercised their over-allotment option, adding another $18 million to its coffers. Irvine, Calif.-based Axonics, which makes the r-SNM device sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention, said the underwriters picked up 1.2 million shares at $15 each, taking gross proceeds from the flotation to $138 million. Axonics closed the IPO Nov. 2, after first setting a range of $93.3 million to $106.7 million which it&nbs...
Source: Mass Device - November 19, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Funding Roundup Initial Public Offering (IPO) Neuromodulation/Neurostimulation Wall Street Beat Axonics Modulation Technologies Source Type: news

Valencia Techs updates on eCoin OAB trials
Valencia Technologies this week updated on the pivotal trial of its eCoin overactive bladder neurostim device, saying it has enrolled more than 35 patients and that it expects to finish implantations by January next year, with a hopeful completion date of January 2020. The system, which is approximately the size of a nickel, is designed to implanted in a 10 minute procedure and send electrical impulses to the tibial nerve to stimulate the part of the brain that controls bladder response, the New York-based company said. The single-arm pivotal trial, which won approval by the FDA in March, aims to enroll a total of 120...
Source: Mass Device - November 2, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Featured Urology Valencia Technologies Source Type: news

Medibio names medical-device veteran Kaysen CEO
Medibio Ltd., which develops technology that aims to diagnose mental-health conditions, has named medical-device industry veteran David Kaysen its CEO and managing director. Kaysen was most recently CEO of a Sun BioPharma Inc., a biotech company developing drugs to treat diseases affecting the pancreas. He was previously the top executive at medical-device maker Uroplasty Inc., which makes devices that treated overactive bladder and incontinence. (He's also the father of renowned Minneapolis chef… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 2, 2018 Category: Pharmaceuticals Authors: Katharine Grayson Source Type: news

Axonics closes $120m IPO
Axonics Modulation Technologies (NSDQ:AXNX) today closed its $120 million initial public offering, saying it could reap still more from the flotation if an underwriters option is exercised. Irvine, Calif.-based Axonics, which makes the r-SNM device sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention, had set the range for the flotation at $93.3 million to $106.7 million, but later increased the number of shares to 8 million, priced at $15 each. The 30-day, 1.2-million-share over-allotment, if fully exercised, would add $18 million to the IPO&...
Source: Mass Device - November 2, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Funding Roundup Initial Public Offering (IPO) Neuromodulation/Neurostimulation Wall Street Beat Axonics Modulation Technologies Source Type: news

Axonics prices upsized $120m offering
Axonics Modulation Technologies yesterday priced an upsized initial public offering that could fetch a maximum of $138 million. Irvine, Calif.-based Axonics, which makes the r-SNM device sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention, last week set the range for the flotation at $93.3 million to $106.7 million, saying it would issue nearly 6.7 million shares at $14 to $16 apiece. Yesterday the company increased the number of shares to 8 million, priced at $15 each, for gross proceeds of $120 million. If a 30-day, 1.2-million-share over-a...
Source: Mass Device - October 31, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Funding Roundup Initial Public Offering (IPO) MassDevice Earnings Roundup Neuromodulation/Neurostimulation Wall Street Beat Axonics Modulation Technologies Source Type: news

Axonics sets range for $100m IPO
Axonics Modulation Technologies yesterday set the range on an initial public offering that would fetch $100 million at the midpoint. The Irvine, Calif.-based company makes the r-SNM device sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention. Axonics touts it as the first such rechargeable device; it’s designed to deliver mild electrical stimulation using a four-electrode lead introduced through the sacrum and a pulse generator implanted in the upped buttocks. Axonics said it plans to float nearly 6.7 million shares at $14 to $16 apiece, for a gro...
Source: Mass Device - October 23, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Funding Roundup Neuromodulation/Neurostimulation Wall Street Beat Axonics Modulation Technologies Source Type: news

How do pelvic floor muscle exercises reduce overactive bladder symptoms?
(Wolters Kluwer Health) Overactive bladder (OAB) is a common form of urinary incontinence that is widely treated with pelvic floor muscle (PFM) training. A new laboratory study lends insights into how PFM training works: by reducing contractions of the detrusor muscle of the bladder, reports the American Journal of Physical Medicine& Rehabilitation, the official journal of the?Association of Academic Physiatrists. The journal is published by Wolters Kluwer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 19, 2018 Category: International Medicine & Public Health Source Type: news

Velicept raises another $15M to advance overactive bladder treatment
Velicept Therapeutics said Tuesday it raised an additional $15 million through an expansion of its series B financing. The Malvern pharmaceutical company plans to use the funding to support the completion of two mid-stage clinical trials of its lead new drug candidate Solabegron, which it is developing as a treatment for people with overactive bladders. Dr. James Walker, president and CEO of Velicept, said the fu nding will also enable the company to prepare for phase-III clinical studies — the… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 17, 2018 Category: Biotechnology Authors: John George Source Type: news

Axonics Modulation files for $86m IPO
Axonics Modulation Technologies last week registered for an initial public offering worth more than $86 million for its neuromodulation system for treating urinary and bowel conditions. The Irvine, Calif.-based company touts its r-SNM device as the first rechargeable sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention. It’s designed to deliver mild electrical stimulation using a four-electrode lead introduced through the sacrum and a pulse generator implanted in the upped buttocks. Th r-SNM device won CE Mark approval in the European Union in June 201...
Source: Mass Device - October 9, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Funding Roundup Initial Public Offering (IPO) Neuromodulation/Neurostimulation Wall Street Beat Axonics Modulation Technologies Source Type: news

Simple nerve stimulation may improve sexual response in women
(Michigan Medicine - University of Michigan) Electrodes aren't the first thing most people think of when it comes to achieving sexual arousal. But if the results of a pilot study are any indication, that may soon change. Michigan Medicine researchers find that a treatment typically used for overactive bladder may also be effective for female sexual dysfunction. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 5, 2018 Category: International Medicine & Public Health Source Type: news

BlueWind posts positive follow-up study results
BlueWind Medical’s implantable tibial stimulation device Neurostim developer BlueWind Medical reported positive results from a follow-up study of patients using its implantable tibial nerve stimulator for overactive bladder (OAB). Renova iStim is a leadless, miniature, wireless neurostimulation platform designed for the treatment of multiple clinical indications. Three years after implantation of the BlueWind’s Renova iStim device, 75% of patients experienced at least a 50% long-term reduction in symptoms. Patients experienced a durable, long-term, effect of urinary urge incontinence relief in &l...
Source: Mass Device - August 31, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Food & Drug Administration (FDA) Implants Neuromodulation/Neurostimulation Research & Development Urology Bluewind Medical Source Type: news

Restore your bladder, LOSE YOUR MIND: Oxybutynin bladder drug found to drastically increase the risk of dementia
(Natural News) A common drug for urinary incontinence may increase the risk of dementia, according to a recent study. Researchers said the bladder drug oxybutynin, which helps relieve muscle spasms that trigger overactive bladder syndrome, was consistently shown to raise the risk of dementia and impaired cognitive function when taken orally. According to the study, 16... (Source: NaturalNews.com)
Source: NaturalNews.com - August 7, 2018 Category: Consumer Health News Source Type: news

Nuvectra Suffers Painful Stock Drop After Regulatory Update
A company that spun out of Greatbatch in 2016 experienced a painful drop in its stock price Monday after updating investors on its regulatory progress for a sacral neuromodulation (SNM) system designed to treat chronic urinary retention and the symptoms of overactive bladder. Plano, TX-based Nuvectra said FDA has asked for additional information related to any modifications or changes to its Virtis device, labeling, and manufacturing as well as clarifications of data related to MRI. The company also has been asked to submit clinical study data to the European Union regulatory before it can recommend CE mark ...
Source: MDDI - July 3, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

18 years old and still wetting the bed: Teenager speaks out about his lifelong bladder problem
Seb Cheer, 18, from Cardiff, has suffered with an overactive bladder for his whole life but, now at Leeds University, he is encouraging other young people to discuss the condition. (Source: the Mail online | Health)
Source: the Mail online | Health - June 29, 2018 Category: Consumer Health News Source Type: news

BlueWind Medical Receives FDA Approval for Pivotal Trial Design of RENOVA iStim(TM) Implantable Tibial Nerve Neuromodulator for Overactive Bladder
HERZLIYA, Israel, June 14, 2018 -- (Healthcare Sales & Marketing Network) -- BlueWind Medical, a developer of a miniature wireless neurostimulation platform, for the treatment of multiple clinical indications, announced today that the US Food and Drug Adm... Devices, Urology, Neurology, FDA BlueWind Medical, RENOVA iStim, overactive bladder, Tibial Stimulation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 14, 2018 Category: Pharmaceuticals Source Type: news

Medical News Today: Foods for bladder health
Having an overactive bladder can be a very challenging condition, but there are many ways in which people can improve their symptoms. These include monitoring the foods and drinks that they consume, as well as avoiding alcohol, caffeine, and spicy foods. Learn more about the overactive bladder diet here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 18, 2018 Category: Consumer Health News Tags: Overactive Bladder (OAB) Source Type: news

Neuromodulation Continues to be Activity Hotbed
The Neuromodulation market is rapidly growing and has become host to many medtech companies. StimGuard is the latest firm to make significant moves in the space, as it has received CE mark for a wireless neuromodulation device to treat chronic symptoms of overactive bladder. The Pompano Beach, Fla.-based company said its StimGuard would be available in Europe in the summer of 2018. “A wireless system that enables urologists to inject such a clinically proven therapy represents a shift in the field where there has only been one option for over 15 years,” Karl-Dietrich Sievert MD, PhD, professor and co-chairman o...
Source: MDDI - May 18, 2018 Category: Medical Devices Authors: Omar Ford Tags: Implants Source Type: news

StimGuard wins CE Mark for SNS overactive bladder treatment
StimGuard said today it won CE Mark approval in the European Union for its sacral nerve stimulator designed to treat intractable symptoms of overactive bladder, with plans to launch the device in the EU this summer. The Pompany Beach, Fla.-based company touted that the StimGuard SNS system can be implanted through a needle without a surgery, as the device is 95% smaller than other similar sacral nerve stimulation devices on the market. The system uses an Apple iPad as a programming console, the company added. “A wireless system that enables urologists to inject such a clinically proven therapy represents a shift...
Source: Mass Device - May 17, 2018 Category: Medical Devices Authors: Fink Densford Tags: Neuromodulation/Neurostimulation Regulatory/Compliance StimGuard Source Type: news

FDA Approves Mirabegron, Solifenacin Combo for OAB FDA Approves Mirabegron, Solifenacin Combo for OAB
The FDA has approved mirabegron (Myrbetriq, Astellas Pharma) in combination with solifenacin succinate for the treatment of overactive bladder (OAB).FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 9, 2018 Category: Consumer Health News Tags: Urology News Alert Source Type: news

FDA Approves Supplemental New Drug Application for Myrbetriq (mirabegron) for Use in Combination with Solifenacin Succinate for the Treatment of Overactive Bladder Symptoms
TOKYO, May 7, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 7, 2018 Category: Drugs & Pharmacology Source Type: news

Urovant Sciences Strengthens Executive Management Team with Senior Hires and Establishes U.S. Headquarters in Irvine, California
Cornelia Haag-Molkenteller, former VP and Therapeutic Area Head, Clinical Development, for Urology, Women's Health, and Internal Medicine at Allergan, joins as Chief Medical Officer Michael McFadden, former SVP for Commercial at Avanir, joins as Chief C... Biopharmaceuticals, Urology, Personnel Urovant Sciences, Vibegron, overactive bladder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 24, 2018 Category: Pharmaceuticals Source Type: news

Laborie Medical closes $214m Cogentix buy
Laborie Medical Technologies said today that it closed the $214 million acquisition of Cogentix Medical (NSDQ:CGNT). With about 85% of the urology and gynecology device maker’s shares tendered over the weekend, meeting the minimum tender requirement, the stage was set for the deal to close today. The $3.85-per-share cash tender pulled in some 51.5 million shares, for about $198.2 million, Laborie said April 21. The deal represents a 14.2% premium over CGNT stock’s $3.37 closing price March 9, the last business day before the deal was announced. “Our combined, complementary pr...
Source: Mass Device - April 23, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Urology Women's Health Cogentix Medical Laborie Medical Technologies Source Type: news

Medical News Today: How many times a day should a person pee?
A person will usually urinate more frequently at certain times of day and when they are well hydrated. However, some medical conditions cause a person to pee too often or not often enough. Pregnancy and advancing age can also play a role. Here, learn what causes irregular or frequent urination and how to manage it. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 11, 2018 Category: Consumer Health News Tags: Overactive Bladder (OAB) Source Type: news

Medical News Today: Is it safe to hold your pee? Five possible complications
It is usually best to go to the bathroom when the urge hits, but sometimes life gets in the way. Here, learn about the possible complications of holding in pee, including urinary tract infections, damaged pelvic floor muscles, cramping, kidney stones, and more. We also discuss tips for reaching a toilet in time. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 5, 2018 Category: Consumer Health News Tags: Overactive Bladder (OAB) Source Type: news

Medical News Today: What causes urine leakage while coughing?
Peeing while coughing is a form of stress incontinence. It can happen to men and women and is associated with physical activity, such as running or jumping, when pressure is put on the bladder and urine is released unintentionally. Learn about this condition here, including causes, management, and what to do. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 29, 2018 Category: Consumer Health News Tags: Overactive Bladder (OAB) Source Type: news

Herbal blend that includes horsetail found to reduce urinary incontinence and overactive bladder, without the side effects of prescriptions
(Natural News) If you suffer from urinary incontinence or overactive bladder, you’re probably losing patience with the frequent bathroom visits and night awakenings this condition can cause. Perhaps you’ve tried prescription drugs to no avail, or you’re not willing to take on their risks. Now, evidence shows that an herbal blend containing horsetail could help... (Source: NaturalNews.com)
Source: NaturalNews.com - March 15, 2018 Category: Consumer Health News Source Type: news

Laborie Set to Acquire Cogentix
Laborie Medical Technologies is set to acquire Cogentix Medical for about $239 million in a deal that will close in the second quarter of 2018. The price represents a 28% premium over Cogentix average 30-day closing price. Minnetonka, MN-based Cogentix specializes in urology devices. The firm’s products include Urgent PC, a neuromodulation system for percutaneous tibial nerve stimulation. It treats overactive bladder and associated symptoms of urinary urgency, urinary frequency, and urge incontinence on an outpatient basis. Join us at the BIOMEDevice Boston Expo,  April 18–19, 2018. Use promo code "MD...
Source: MDDI - March 13, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Laborie Medical to pay $214m for Cogentix
Laborie Medical Technologies said today that it agreed to pay $214 million for Cogentix Medical (NSDQ:CGNT) and its line of urology and gynecology devices. Formed by the 2015 merger of Vision-Sciences and Uroplasty, Minnetonka, Minn.-based Cogentix makes the Urgent PC neuromodulation device for treating overactive bladder syndrome, the PrsimeSight cystoscopy and EndoSheath devices and Macroplastique, an injectable soft-tissue bulking agent for treating female stress urinary incontinence. The $3.85-per share cash offer is slated to close during the first half of the year, Toronto-based Lab...
Source: Mass Device - March 12, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Urology Wall Street Beat Women's Health Cogentix Medical Laborie Medical Technologies Source Type: news

Valencia Tech wins FDA nod for eCoin neurostim overactive bladder trial
Valencia Technologies said today it won FDA investigational device exemption approval to launch a pivotal trial of its eCoin neurostimulation device exploring its ability to treat overactive bladder. The system, which is approximately the size of a nickel, is designed to implanted in a 10 minute procedure and send electrical impulses to the tibial nerve to stimulate the part of the brain that controls bladder response, the New York-based company said. “There is great excitement for a therapy that delivers more than modest improvement in overactive bladder symptoms while avoiding the side-effects of drugs,”...
Source: Mass Device - March 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Regulatory/Compliance Valencia Technologies Source Type: news

FDA Approves Pivotal Clinical Trial for Technology to Treat Overactive Bladder
NEW YORK, March 9, 2018 -- (Healthcare Sales & Marketing Network) -- Yesterday, the FDA approved the conduct of a pivotal clinical trial using a new technology to treat overactive bladder. The technology, developed and manufactured by Valencia Technologie... Devices, Urology, FDA Valencia Technologies, overactive bladder, eCoin , neuromodulation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 9, 2018 Category: Pharmaceuticals Source Type: news

StimGuard launches head-to-head trial against Medtronic ’ s InterStim
StimGuard yesterday announced plans for a clinical trial comparing its nerve stimulator with the InterStim sacral nerve stimulator made by Medtronic (NYSE:MDT). Pompano Beach, Fla.-based StimGuard is already running a pivotal study of its technology, a miniature implantable device designed to treat urinary incontinence resulting from refractory overactive bladder syndrome. The device is implanted at the tibial nerve through a needle-sized introducer and uses wireless technology to stimulate the nerve. The new study is designed to compare that treatment with InterStim sacral nerve stimulation therapy, which i...
Source: Mass Device - March 1, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Neuromodulation/Neurostimulation Urology Women's Health Medtronic StimGuard Source Type: news

Overactive bladder treatment may also lead to better sleep
(Reuters Health) - Women with overactive bladder who take medication to address the problem may feel the urge to urinate less often and also sleep better at night as a result, a U.S. study suggests. (Source: Reuters: Health)
Source: Reuters: Health - February 1, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

5 medtech stories we missed this week: Jan. 26, 2018
[Image from unsplash.com]From Attune Medical receiving FDA 510(k) clearance to Synapse Medical having CE Mark approval, here are 5 medtech stories we missed this week but thought were still worth mentioning. 1. Attune Medical gets FDA 510(k) clearance Attune Medical announced in a Jan. 8 press release that it has received FDA 510(k) clearance for its EnsoETM model that administers tube feeds or medication while cooling or warming patients. The device manages a patient’s temperature through the esophagus while allowing for enteral fluid administration with the company’s ENFit connector. 2. Ally Bridge, Life...
Source: Mass Device - January 26, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Food & Drug Administration (FDA) Hospital Care Neuromodulation/Neurostimulation Regulatory/Compliance Respiratory Ally Bridge Group Attune Medical Axonics Modulation Technologies LifeTech Scientific Corp. MedTech ResMed Inc. Source Type: news

Axonics touts first patients treated in sacral neuromod study
Axonics Modulation Technologies said today that the first 11 patients in its Artisan-SNM sacral neuromodulation study have been implanted with the company’s device designed to treat urinary and bowel dysfunction. The patients were implanted at four centers across the US and Western Europe, the Irvine, Calif.-based company said. The trial will look to enroll 120 patients across 15 centers in total. The single-arm, prospective pivotal study, which won FDA approval last November, is examining the safety and effectiveness of the r-SNM system as an aid to treating urinary urgency incontinence with patients who failed...
Source: Mass Device - January 3, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blog Axonics Modulation Technologies Source Type: news

Cogentix touts MAC coverage extension for OAB neuromod treatment
Cogentix Medical (NASDAQ: CGNT) said today that Medicare Administrative Contractor Palmetto GBA extended granted coverage for percutaneous tibial nerve stimulation procedures to treat overactive bladder with the company’s PC Neuromod System. With the extension, patients with Medicare coverage in North Carolina, South Carolina, parts of Virginia and West Virginia will be eligible to receive PTNS therapy for up to 3 years, adding an additional year onto previous coverage, the Minneapolis, Minn.-based company said. “On behalf of the many overactive bladder patients who can benefit from Urgent PC&rsq...
Source: Mass Device - December 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Urology Cogentix Medical Source Type: news

Outpost Medicine Appoints Scott Byrd as Chief Executive Officer and Raises $20 Million in Series A Financing Extension
New Investor Takeda Ventures Joins Syndicate; Proceeds to Fund Lead Clinical Stage Program for the Treatment of Overactive Bladder and Irritable Bowel Syndrome INDIANAPOLIS and LONDON, Nov. 15, 2017 -- (Healthcare Sales & Marketing Network) -- Outpost ... Biopharmaceuticals, Venture Capital, Personnel Outpost Medicine, Irritable Bowel Syndrome, Overactive Bladder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 15, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Axonics IDE trial for r-SNM neuromod
Axonics Modulation Technologies said today it won FDA investigational device exemption clearance to engage in a pivotal study of its r-SNM rechargeable sacral neuromodulation system designed for treating overactive bladder and bowel dysfunction. The Irvine, Calif.-based company said it expects to begin enrolling patients in the clinical study in November, aiming to enlist 120 patients at 15 centers in the US and Western Europe. “During 2017, as part of the IDE process, the FDA conducted a significant review of our product. A major focus of the technical review was the long-term safety of our implant. The fact th...
Source: Mass Device - November 7, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Regulatory/Compliance Axonics Modulation Technologies Source Type: news

Digging For Gold
This article appeared in the most recent edition of our specialist publication,Trends in Medical Affairs.Click here to download a copy.   Related Content: Pragmatic Trials: The Real-World Data RevolutionNavigating The New LandscapeWhen Real-World Evidence met Patient-CentricityBig Data, Huge OpportunityPrimary Event: Medical Affairs Europe 2018Pr écis: As Medical gets more involved in real-world evidence, what challenges does it face in proving the value of a medicine?Premium`: Freemium`: Channels: CommercialTags: medical affairsChannelimage:  (Source: EyeForPharma)
Source: EyeForPharma - November 1, 2017 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Digging For Gold
This article appeared in the most recent edition of our specialist publication,Trends in Medical Affairs.Click here to download a copy.   Related Content: Pragmatic Trials: The Real-World Data RevolutionNavigating The New LandscapeWhen Real-World Evidence met Patient-CentricityBig Data, Huge OpportunityPrimary Event: Medical Affairs Europe 2018Pr écis: As Medical gets more involved in real-world evidence, what challenges does it face in proving the value of a medicine?Premium`: Freemium`: Channels: Patients and MedicalTags: medical affairsChannelimage:  (Source: EyeForPharma)
Source: EyeForPharma - November 1, 2017 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Prostate problem? Take 2 nuts
By age 60, you have a 50/50 chance of having a clinically enlarged prostate. And it only gets worse every year. When your prostate isn’t functioning properly, it’s hard to enjoy life. Traditional doctors give you two choices. Go under the knife or you take Big Pharma’s drugs. Either way, you have a good chance of ending up with your manhood on the line… If you have surgery, there’s a big risk you’ll be saying goodbye to your sex life for good. The rate of impotence is a shocking 50 to 60% after prostate surgery.1 Big Pharma’s meds to shrink your prostate are no better. These sy...
Source: Al Sears, MD Natural Remedies - October 19, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news